Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss the treatment choice between targeted therapy and immunotherapy in a patient with an EGFR Mutation and high PDL-1.
Case Based Panel Discussion - Choosing Between Targeted Therapy and Immunotherapy in a Patient with an EGFR Mutation and High PDL-1 Expression
Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss a frail patient with metastatic squamous NSCLC with low tumor PD-L1 expression, and the best treatment approach for this patient.
Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss treating a patient with rapidly progressing lung adenocarcinoma and high tumor PD-L1 expression.
, , , ,
The Global Resource for Advancing Cancer Education (GRACE), presents Molecular Diagnostic Testing and Next Generation Sequencing in Lung Cancer webinar series.
, , , ,
The Global Resource for Advancing Cancer Education (GRACE), in partnership with Georgetown University Hospital is pleased to present the videos from the panel discussion "2017 Advances in Immunotherapy: What Lung Cancer Patients Need to Know".
GRACE is excited to continue to build the faculty and agenda for the upcoming Targeted Therapies Patient Forum, September 16, 2017. See more information about our presenters in Speaker Highlights - today we introduce James Stevenson, MD.
Christine M. Walko, Pharm.D., discusses how advancements in technology have improved the quality, cost and turnaround time for assessing genetic mutations in tumor tissue, and how this has helped to translate precision medicine into standard clinical practice.
Imprecision Medicine: Why Keytruda (Pembrolizumab) + Chemo for PD-L1+ NSCLC isn't Ready for Prime Time
Let me start by saying that I'm a fan of the immune checkpoint inhibitor Keytruda (pembrolizumab) and consider it the new standard of care as a...
First Line Immunotherapy for Advanced Non-Small Cell Lung Cancer: A Great Option for Some, but Not for All
Several weeks ago, at a very crowded plenary session for the European Society of Medical Oncology (ESMO) in Copenhagen, Denmark, results with first...
Amidst all of the glowing reports about immunotherapy for lung and many other cancers, it would be understandable for patients and physicians to be tempted to rush toward prioritizing immunotherapy as the first treatment strategy to pursue. In fact ...
My wife is experiencing a second time brain tumor recurrence. She had her first occipital craniotomy back in 2011. On late Oct 2013 she began to...
My father has been dealing with prostate cancer for a couple of years now and is about to begin treatment. Does anybody have any information or...
Has anyone any information on obtaining and using Vaxira, the Cuban drug, for stage 4 advanced NSCLC? Not sure if US citizens can still travel to...
My wife was on Tarceva for over 6 1/2 years. Then she developed acquired resistance to Tarceva with prevascular and supraclevical lymph nodes...
My wife has come a long way with Stage IV lung cancer since 2010. She has now developed acquired resistance to Tarceva. Gene sequence of biopsy from...